ライフサイエンスコーパス: first-line chemotherapy

1 is extremely poor, as they are resistant to first line chemotherapy.

2 plete or partial remission or no-response to first-line chemotherapy.

3 al prognosis and few treatment options after first-line chemotherapy.

4 FS differences in patients undergoing ICB or first-line chemotherapy.

5 ve to BSC alone as maintenance therapy after first-line chemotherapy.

6 o therapeutic benefit of adding veliparib to first-line chemotherapy.

7 mph node dissection (pcRPLND) specimen after first-line chemotherapy.

8 ated with pcRPLND <=57 versus >57 days after first-line chemotherapy.

9 ave poor prognosis after failure of standard first-line chemotherapy.

10 response evaluation after the completion of first-line chemotherapy.

11 iotic in the month before or after beginning first-line chemotherapy.

12 d 1 immunotherapy for patients who initiated first-line chemotherapy.

13 cer who experience disease progression after first-line chemotherapy.

14 er that had progressed following, or during, first-line chemotherapy.

15 h historical data from patients treated with first-line chemotherapy.

16 tation compared with 9% in patients starting first-line chemotherapy.

17 cance of CTCs in patients with MBC receiving first-line chemotherapy.

18 al junction adenocarcinoma progressing after first-line chemotherapy.

19 ptor (EGFR) tyrosine kinase inhibitor, after first-line chemotherapy.

20 ic model to predict OS in patients receiving first-line chemotherapy.

21 t is introduced immediately on completion of first-line chemotherapy.

22 who have experienced treatment failure with first-line chemotherapy.

23 NSCLC treated with cisplatin-gemcitabine as first-line chemotherapy.

24 dies suggested it might be an alternative to first-line chemotherapy.

25 ts were platinum refractory and had an IR to first-line chemotherapy.

26 Of the 21,285 patients, 25.8% received first-line chemotherapy.

27 stration-resistant prostate cancer receiving first-line chemotherapy.

28 all-cell lung cancer (SCLC) after failure of first-line chemotherapy.

29 ecision compared with women who were offered first-line chemotherapy.

30 1 patients after a complete response (CR) to first-line chemotherapy.

31 d with 2.3 months (range, 0.2 to 28.1) after first-line chemotherapy.

32 nced disease stage (34.1% vs 19.8%), receive first-line chemotherapy (33.8% vs 18.2%), and have worse

33 At first line chemotherapy, 44 patients received one day GE

34 h RAS-mut predominant MAAP responded more to first-line chemotherapy (50%) compared with patients wit

35 an cancer (EOC) after surgical resection and first-line chemotherapy, about 60% of patients will re-d

36 ugs that induce DNA damage are commonly used first-line chemotherapy agents for testicular, bladder,

37 total of 1476 Canadian patients who received first-line chemotherapy and 287 patients who received fi

38 enteen interviews included 70 in relation to first-line chemotherapy and 47 in relation to second-lin

39 All patients were refractory to first-line chemotherapy and 88% had received prior radio

40 ovarian cancer when used in combination with first-line chemotherapy and as a single-drug continuatio

41 In this study, we evaluate benefit from first-line chemotherapy and characterize imaging respons

42 ival [PFS] and overall survival [OS]) during first-line chemotherapy and ICB, as well as baseline whi

43 roven APC were randomly assigned to ambulant first-line chemotherapy and prophylactic use of enoxapar

44 dered a highly curable disease with standard first-line chemotherapy and radiotherapy in some cases.

45 l 20 patients who recurred were treated with first-line chemotherapy and remained continuously diseas

46 we further assess TG4010 in combination with first-line chemotherapy and use of the TrPAL biomarker i

47 ge IV NSCLC who have received four cycles of first-line chemotherapy and whose disease has not progre

48 gogastric (EGC) cancer who were treated with first-line chemotherapy and/or ICB at Memorial Sloan Ket

49 A total of 13 532 US patients received first-line chemotherapy, and 2137 received first-line pe

50 , pyrazinamide, or rifampicin, components of first-line chemotherapy, and moxifloxacin individually a

51 al therapy and consolidation treatment after first-line chemotherapy are as yet undefined.

52 dvanced ovarian cancer, rates of response to first-line chemotherapy are high but most patients have

53 n patients treated with EGFR inhibitors plus first-line chemotherapy are unknown.

54 of patients with disseminated GCT receiving first-line chemotherapy at Princess Margaret Cancer Cent

55 treated with cisplatin- and etoposide-based first-line chemotherapy between 1990 and 2013 were colle

56 treated with cisplatin- and etoposide-based first-line chemotherapy between 1990 and 2013 were colle

57 Data on 117 men treated with cisplatin-based first-line chemotherapy between 1990 and 2018 were colle

58 Patients obtaining a CR after first-line chemotherapy can be safely observed without P

59 trate, partly because some patients who fail first-line chemotherapy can be salvaged in second remiss

60 iable salvage treatment for patients in whom first-line chemotherapy cannot control the disease.

61 EOC have a poorer response to platinum-based first-line chemotherapy compared with patients with othe

62 ith doxorubicin and cyclophosphamide (AC) as first-line chemotherapy (CT) in metastatic breast cancer

63 -of-care treatments fail to respond to their first-line chemotherapy, demonstrating the pressing need

64 tments and biomarkers: (1) After a period of first-line chemotherapy, do targeted novel therapies pro

65 First-line chemotherapy (docetaxel), abiraterone, enzalu

66 Doxorubicin, a first-line chemotherapy drug, often causes myelosuppress

67 persistently increased CTCs after 21 days of first-line chemotherapy, early switching to an alternate

68 First-line chemotherapy fails in more than 20% of patien

69 vival compared with the standard sequence of first-line chemotherapy followed by erlotinib.

70 tly worse OS and PFS than patients receiving first-line chemotherapy followed by resection.

71 Cisplatin is a first line chemotherapy for most types of cancer.

72 Cisplatin-based treatment is the first line chemotherapy for several cancers including ov

73 with historical outcomes achieved with other first-line chemotherapies for advanced STS.

74 dult women who had progressive disease after first-line chemotherapy for advanced or metastatic endom

75 First-line chemotherapy for advanced or metastatic human

76 First-line chemotherapy for advanced pancreatic cancer.

77 Patients age >/= 70 years receiving first-line chemotherapy for cancer were prospectively co

78 cal response rates to docetaxel, the current first-line chemotherapy for castration-resistant disease

79 Standard first-line chemotherapy for endometrial cancer is paclit

80 Standard-of-care first-line chemotherapy for epithelial ovarian cancer is

81 ministered every 3 weeks is standard-of-care first-line chemotherapy for epithelial ovarian cancer.

82 ional advantage to using EP instead of EC as first-line chemotherapy for MBC in taxane-naive patients

83 imastat does not prolong PFS when used after first-line chemotherapy for metastatic breast cancer.

84 teoclasts, and has synergy with docetaxel, a first-line chemotherapy for metastatic castration-resist

85 dies suggests that disease progression after first-line chemotherapy for metastatic non-small-cell lu

86 m-based drugs such as cisplatin (CP) are the first-line chemotherapy for non-small-cell lung carcinom

87 First-line chemotherapy for patients with cisplatin-inel

88 heckpoint inhibitors improve the efficacy of first-line chemotherapy for patients with programmed dea

89 Cisplatin is the first-line chemotherapy for the treatment of several can

90 than 70 years of age who were scheduled for first-line chemotherapy for various types of cancer were

91 e combination of paclitaxel and cisplatin as first-line chemotherapy for women with advanced breast c

92 Of those, 8447 patients (62.4%) in the first-line chemotherapy group and 1653 patients (77.3%)

93 on (0.56% over 60 months of follow-up in the first-line chemotherapy group and 4.54% over 30 months o

94 who have disease progression during or after first-line chemotherapy have limited treatment options.

95 mpared with no treatment, patients receiving first-line chemotherapy (hazard ratio [HR], 1.44; 95% CI

96 a VEGFR-2 antagonist monoclonal antibody, to first-line chemotherapy improves outcomes in patients wi

97 Addition of trastuzumab to first-line chemotherapy improves overall survival in pat

98 assessed in combination with platinum-based first-line chemotherapy in a large phase 3 trial.

99 ernational, prospective, randomized trial of first-line chemotherapy in advanced ovarian cancer (doce

100 h a manageable safety profile, when added to first-line chemotherapy in advanced squamous cell carcin

101 trial is comparable to results observed with first-line chemotherapy in chemotherapy-naive patients.

102 with metastatic colorectal cancer receiving first-line chemotherapy in combination with either bevac

103 sibility study of cisplatin and docetaxel as first-line chemotherapy in International Federation of G

104 rastuzumab increases the clinical benefit of first-line chemotherapy in metastatic breast cancer that

105 s of advanced pancreatic cancer treated with first-line chemotherapy in Ontario, Canada that were ide

106 advanced pancreatic cancer were treated with first-line chemotherapy in Ontario, Canada.

107 vival when used in combination with standard first-line chemotherapy in patients with advanced NSCLC

108 The addition of SIRT to FOLFOX-based first-line chemotherapy in patients with liver-dominant

109 ker (at ~4 wk) for evaluation of response to first-line chemotherapy in patients with pancreatic duct

110 ination with oxaliplatin and capecitabine in first-line chemotherapy in patients with widespread meta

111 astration-resistant prostate cancer starting first-line chemotherapy in the IMMC38 trial.

112 We conclude that first-line chemotherapy including rituximab is associate

113 stablish whether maintenance lapatinib after first-line chemotherapy is beneficial in human epidermal

114 primary chemosensitivity observed during the first-line chemotherapy might be another complementary d

115 een treated previously with radiotherapy and first-line chemotherapy or concurrent chemoradiotherapy.

116 variable analyses, in 625 patients receiving first-line chemotherapy or radiotherapy (with or without

117 l cancer that progressed, were intolerant to first-line chemotherapy, or had disease recurrence withi

118 ts with stage IV colorectal cancer receiving first-line chemotherapy, particularly in black and femal

119 Following first-line chemotherapy, pcRPLND provides effective cont

120 ease progression on or within 4 months after first-line chemotherapy (platinum plus fluoropyrimidine

121 RC who had a partial or complete response to first-line chemotherapy plus an anti-EGFR monoclonal ant

122 T mCRC had a complete or partial response to first-line chemotherapy plus anti-EGFR drugs, developed

123 lioma) is a pivotal trial comparing standard first-line chemotherapy plus pegargiminase or placebo in

124 fied according to their previous response to first-line chemotherapy (primary refractory v primary se

125 ry tumor site and prior complete response to first-line chemotherapy program).

126 site and a prior complete response (CR) to a first-line chemotherapy program, which had been identifi

127 ), female sex (OR, 1.33; 95% CI, 1.14-1.56), first-line chemotherapy received (OR, 1.22; 95% CI, 1.05

128 LFOXIRI-Bev) is an established and effective first-line chemotherapy regimen for metastatic colorecta

129 Cisplatin and gemcitabine is the standard first-line chemotherapy regimen for patients with advanc

130 maintenance erlotinib to bevacizumab after a first-line chemotherapy regimen with bevacizumab for adv

131 stration of a lower intensity version of the first-line chemotherapy regimen).

132 Cisplatin and gemcitabine is the standard first-line chemotherapy regimen, but no robust evidence

133 outcomes regardless of HIV status, stage, or first-line chemotherapy regimen.

134 gemcitabine plus docetaxel is an appropriate first-line chemotherapy regimen.

135 scan result, number of metastatic sites, and first-line chemotherapy regimen.

136 intraoperative peritoneal cancer index, and first-line chemotherapy response were assessed adjusting

137 Standard first-line chemotherapy results in disease progression a

138 The addition of cetuximab to first-line chemotherapy seems to benefit patients with K

139 ould be an alternative or even the preferred first-line chemotherapy strategy for patients with metas

140 ge IIIB/IV recurrent NSCLC progressing after first-line chemotherapy, stratified by ECOG performance

141 tients with liver-only disease included in a first-line chemotherapy study, the NORDIC VII study (n =

142 of BAX achieved a complete response (CR) to first-line chemotherapy that contained paclitaxel plus a

143 he addition of immune checkpoint blockade to first-line chemotherapy, the prognosis for patients with

144 tients who had previously achieved a CR to a first-line chemotherapy trial, 17 were identified as hav

145 erapy, and is similar to the results of many first-line chemotherapy trials in this setting.

146 led with patients with distant metastases in first-line chemotherapy trials not suited to define the

147 the decision-making process (33%, n = 23 at first-line chemotherapy v 43%, n = 20 at second-line che

148 atient interviews; 19%, n = 13 being offered first-line chemotherapy v 43%, n = 20 being offered seco

149 odel for OS in patients with mCRPC receiving first-line chemotherapy was developed and validated on a

150 1 January 2000 and 18 January 2023 following first-line chemotherapy were included.

151 e cancer, age > or = 65 years, and receiving first-line chemotherapy were included.

152 an advanced cancer diagnosis and failure of first-line chemotherapy were interviewed at baseline reg

153 Patient receiving first-line chemotherapy were planned to undergo baseline

154 e IIIB-IV) NSCLC after progression following first-line chemotherapy were randomly assigned 1:1 throu

155 and long-term outcomes of pcRPLND following first-line chemotherapy with a focus on residual mass si

156 treatment cycle is predictive of outcome to first-line chemotherapy with bevacizumab in patients wit

157 randomly assigned patients with mCRC between first-line chemotherapy with cetuximab (anti-EGFR-chemot

158 d germ cell tumors (GCTs) who relapsed after first-line chemotherapy with cisplatin and etoposide wit

159 e in PSA within 3 months after initiation of first-line chemotherapy with docetaxel, are associated w

160 studies evaluated the efficacy of combining first-line chemotherapy with SIRT using yttrium-90 resin

161 of HER2-positive gastric cancer treated with first-line chemotherapy with trastuzumab.

162 cond-line treatment in patients who received first-line chemotherapy, without prior immune checkpoint

163 her changing chemotherapy after one cycle of first-line chemotherapy would improve the primary outcom